CTMX CytomX
- 1.640
- -0.030-1.80%
- 1.680
- +0.040+2.44%
CytomX News
CytomX Therapeutics Analyst Ratings
Piper Sandler Upgrades CytomX Therapeutics to Overweight, Raises Price Target to $3.5
BMO Capital Maintains Market Perform on CytomX Therapeutics, Raises Price Target to $3.59
HC Wainwright & Co. : The CytomX Therapeutics (CTMX.US) neutral rating was reaffirmed.
Wedbush: Upgraded CytomX Therapeutics (CTMX.US) rating from neutral to better than the market rating, and adjusted the target price from $3.00 to $8.00.
CytomX Therapeutics Analyst Ratings
Wedbush Upgrades CytomX Therapeutics to Outperform From Neutral, Adjusts Price Target to $8 From $3
Barclays Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)
CytomX Therapeutics Analyst Ratings
Jefferies Upgrades CytomX Therapeutics to Buy, Price Target at $8
Analysts' Opinions Are Mixed on These Healthcare Stocks: Owens & Minor (OMI), Idexx Laboratories (IDXX) and CytomX Therapeutics (CTMX)
Buy Rating for CytomX Therapeutics on Promising CX-904 Probody Therapy Prospects
CytomX Therapeutics Analyst Ratings
Bank of Montreal, Canada: The CytomX Therapeutics (CTMX.US) rating was confirmed, and the target price was $3.25, from unanimous market to market unanimous rating.
Komo: Upgraded CytomX Therapeutics (CTMX.US) rating from reduced holdings to neutral rating.
CytomX Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Cyclo Therapeutics (CYTH), CytomX Therapeutics (CTMX) and Pacific Biosciences (PACB)
CytomX Therapeutics: A Balanced Hold Rating Amidst Financial Uncertainty and Clinical Progress
CytomX Therapeutics Analyst Ratings
Wedbush Reiterates Neutral on CytomX Therapeutics, Maintains $3 Price Target
Analysis
Price Target
No Data
